

Agenda Biomedical Alliance Spring Meeting

14 May 2019 Square de Meeûs, 29 - Brussels (2nd floor) 10.00-16.30

10.00-16.30	
10.00-10.15 2 nd floor	Welcome coffee
10.15-10.30	Introduction & Tour de table
	Axel Pries
10.30-11.00	European elections: what's at stake?
	Richard Steel, Head of Parliamentary Intelligence Unit at Interel
11.00-13.00	Challenges and Opportunities of the EU's open access plan
	Moderators: Wilfried Ellmeier & Chantal Mathieu
	Plan S is a proposal of the European Commission, Science Europe, and National Research Funding organisations stating that scientific publications that receive funding from its members must be made freely accessible immediately upon publication. This means that researchers who receive public funding from participating organisations will no longer be able to publish in paid, non-open access journals. Plan S thus has substantial consequences for researchers in Europe, but also for health associations that publish in scientific journals.
	Outline: panel discussions
	Keynote: Robert Kiley, Head of Open Science, Wellcome Trust
	Brief introductory interventions (10 min each):
	 Jean-Claude Burgelman, Head of Unit Open data Policies and Science Cloud, European Commission Thomas F. Lüscher, editor in Chief of the European Heart Journal and Valentina Tursini, Scientific Publications Director, ESC Prof. Laszlo Fesus, Chair of the FEBS Publications Committee Jan Cools, editor-in-chief of the HemaSphere journal, EHA
13.00-14.00 4 th floor	Networking lunch



14.00-14.30	Governance Gunhild Waldemar and Michel Ballieu Accounts 2018 BioMed Alliance Membership
14.30-15.20	Update on ongoing activities Influencing Horizon Europe: Steering Board for Health, cooperation with EU based stakeholders to boost health research Axel Pries and Wilfried Ellmeier
	CME Experts Standing Committee David Vodušek
	Task Force on Regulatory Affairs and Medical Devices Alan Fraser
	Task Force on Academic Clinical Trials – what's next Colm O'Morain
15.20-16.00	Future directions Proposal for a regulation on Health Technology Assessment and research community involvement Piotr Szymański
	BioMed Alliance – key player in Brussels ecosystem: relevant stakeholder for EMA, the next Public Private Partnership and the existing Steering mechanisms in the EC
	Axel Pries and Wilfried Ellmeier
	BioMed Alliance position on impact of the GDPR on health research Berthold Koletzko
16.00	Conclusions